Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high grade serous ovarian and breast cancer

Published 2016 View Full Article

Authors

Keywords

Journal

ANNALS OF ONCOLOGY

Volume -, Issue -, Pages mdw672

Publisher

Oxford University Press (OUP)

Online

2016-12-15

DOI

10.1093/annonc/mdw672

Ask authors/readers for more resources

Publish scientific posters with Peeref

Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.

Learn More

Create your own webinar

Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.

Create Now

ANNALS OF ONCOLOGY

Ask authors/readers for more resources

Protocol

Reagent

Reprint

Publish scientific posters with Peeref

Create your own webinar